Zobrazeno 1 - 5
of 5
pro vyhledávání: '"R C, van Waardenburg"'
Autor:
M, Maliepaard, M A, van Gastelen, A, Tohgo, F H, Hausheer, R C, van Waardenburg, L A, de Jong, D, Pluim, J H, Beijnen, J H, Schellens
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 7(4)
This study was aimed at characterizing the role of BCRP/MXR/ABCP (BCRP) in resistance of the human ovarian tumor cell lines T8 and MX3 to camptothecins more extensively and investigating whether resistance can be reversed by inhibiting BCRP by GF1209
Autor:
M, Maliepaard, M A, van Gastelen, L A, de Jong, D, Pluim, R C, van Waardenburg, M C, Ruevekamp-Helmers, B G, Floot, J H, Schellens
Publikováno v:
Cancer research. 59(18)
Topotecan- or mitoxantrone-selected cell lines (T8 and MX3, respectively), derived from the human IGROV1 ovarian cancer cell line, were resistant to the topoisomerase I inhibitors topotecan, SN-38 (the active metabolite of irinotecan), and 9-aminocam
Publikováno v:
Anticancer research. 18(1A)
Amplification and over-expression of oncogenes of the myc family are related to the prognosis of certain solid tumors such as small cell lung cancer (SCLC). For SCLC, c-myc is the oncogene most consistently found to correlate with the end stage behav
Autor:
R C, Van Waardenburg, C, Meijer, H, Burger, K, Nooter, E G, De Vries, N H, Mulder, S, De Jong
Publikováno v:
International journal of cancer. 73(4)
Small-cell-lung-cancer (SCLC) is characterized by rapid development of resistance to cytotoxic agents, such as cisplatin (cDDP) and anthracyclines. c-myc over-expression is one of the reported genetic alterations in this tumor. Amplification of the c
Publikováno v:
Anticancer research. 16(4A)
Small cell lung carcinoma (SCLC) is characterized by rapid development of resistance to drugs, such as cisdiamminedichloroplatinum (II) (cDDP) and anthracyclines. The molecular basis for resistance to cDDP and adriamycin (Adr) is poorly understood. O